Insulet (PODD) 10-K Summary — Year Ended Dec 31, 2025
Insulet Corporation develops and sells the Omnipod platform, a tubeless insulin delivery system for diabetes management. The company reported strong annual revenue growth and positive operating cash flow, while reducing its debt-to-capital ratio.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Insulet Corporation develops and sells the Omnipod platform, a tubeless insulin delivery system for diabetes management. The company reported strong annual revenue growth and positive operating cash flow, while reducing its debt-to-capital ratio.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$2.7B
Revenue reported for the fiscal year.
Operating income
$473.8M
Income from operations reported for the year.
Net income
$247.1M
Net income reported for the year.
Operating cash flow
$569.3M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $1.3B | +18.8% |
| Dec 31, 2023 | $1.7B | +30.0% |
| Dec 31, 2024 | $2.1B | +22.1% |
| Dec 31, 2025 | $2.7B | +30.7% |
Business overview
Insulet is primarily engaged in the development, manufacture, and sale of its proprietary Omnipod product platform, a continuous insulin delivery system for people with insulin-dependent diabetes. The platform includes the Omnipod 5 and Omnipod DASH systems, which eliminate the need for multiple daily injections or traditional pump and tubing. The Omnipod 5 is a tubeless automated insulin delivery system that integrates with a mobile platform.
Financial performance
Revenue increased over the reported period, with operating income and net income both positive. Operating cash flow was also positive, indicating strong cash generation from operations.
Material risks
The filing includes forward-looking statements subject to risks, uncertainties, and assumptions that could cause actual results to differ materially. Specific risk factors are detailed in Item 1A of the filing, though the provided context does not list them individually.
Liquidity and capital
The company believes its current liquidity is sufficient for at least the next twelve months. It reduced its total debt and improved its debt-to-total capital ratio, and had no outstanding borrowings under its revolving credit facility at year-end.
What to watch
Monitor the company's ability to sustain revenue growth and operating cash flow in the next filing.